Author

Mary C. Clark

h-index 15 View on Semantic Scholar

We have 2 of 46 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells

A versatile and modular platform that enables programmable control of CAR T-cell activity is reported, offering a new strategy to overcome tumor heterogeneity and immune suppression.

Cheng-Fu Kuo, Zhen Tong, Yi-Chiu Kuo et al. · Cancer immunology research · 0 citations

Clinical trial Open access Aug 2026

A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm

CD123-directed CAR T-cell therapy is feasible and demonstrates a favorable safety profile in patients with r/r AML and BPDCN, including those with prior alloHCT, according to a phase 1 trial evaluating CD123-targeting chimeric antigen receptor (CAR) T cells in patients with relapsed/refractory AML.

L. Budde, M. D. Del Real, J. Song et al. · Journal of Hematology & Onco... · 0 citations